Shopping Cart
Remove All
Your shopping cart is currently empty
Tabituximab
(Synonyms: OTSA101, OTSA 101, ONC-005, ONC005) Copy Product Info
🥰Excellent
Synonyms: OTSA101, OTSA 101, ONC-005, ONC005
Catalog No. T77449 Copy Product Info
🥰Excellent
Tabituximab (ONC-005) is a humanized monoclonal antibody that targets FZD10 (FZD10), a Wnt receptor, and exhibits antitumor activity. Tabituximab binds to FZD10 on the surface of tumor cells, blocking the binding of Wnt ligands to the receptor, thereby inducing tumor cell apoptosis and inhibiting tumor invasion and metastasis. Tabituximab can be used in research on tumors and immune system diseases.
Cas No. 1644134-10-0
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $360 | - | In Stock | |
| 5 mg | $1,120 | - | In Stock | |
| 10 mg | $1,770 | - | In Stock | |
| 25 mg | $3,360 | - | In Stock | |
| 50 mg | Preferential | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:98.7% (SDS-PAGE); 96.4% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Tabituximab (ONC-005) is a humanized monoclonal antibody that targets FZD10 (FZD10), a Wnt receptor, and exhibits antitumor activity. Tabituximab binds to FZD10 on the surface of tumor cells, blocking the binding of Wnt ligands to the receptor, thereby inducing tumor cell apoptosis and inhibiting tumor invasion and metastasis. Tabituximab can be used in research on tumors and immune system diseases. |
| In vitro | The non-radiolabeled Tabituximab antibody showed only weak inhibition of synovial sarcoma cell growth. [1] |
| In vivo | Yttrium-90 radiolabeled Tabituximab demonstrated significant anti-tumor effects after a single intravenous injection in a mouse xenograft model. [1] |
| Synonyms | OTSA101, OTSA 101, ONC-005, ONC005 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | FZD10 |
| Molecular Weight | 144.63 kDa |
| Cas No. | 1644134-10-0 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | Store at low temperature -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Preview
Related Tags: Tabituximab chemical structure | Tabituximab in vivo | Tabituximab in vitro | Tabituximab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.